BCWM
ROIV icon

Bartlett & Co Wealth Management’s Roivant Sciences ROIV Stock Holding History

Bartlett & Co Wealth Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$177 Buy
+5
New +$148 ﹤0.01% 1279

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Bartlett & Co Wealth Management's ROIV Position: Q2 2026 in Review

Bartlett & Co Wealth Management opened a new position in Roivant Sciences (ROIV) in Q2 2026: 5 shares worth $177. The stake represents ﹤0.01% of the portfolio and ranks #1279 among its holdings.

498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Bartlett & Co Wealth Management held 5 shares of Roivant Sciences worth $177 as of Q2 2026.
  • Roivant Sciences was a new Bartlett & Co Wealth Management position in Q2 2026.
  • Roivant Sciences made up ﹤0.01% of Bartlett & Co Wealth Management's portfolio in Q2 2026, its #1279 holding.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.